hotspot -WSS

hotspot

author：focus 2025-09-27 15:19:43 - browse：5

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Alexander Hamilton and the argument for universal insurance

focus

WSS

Hospitals, health systems can help patients avoid medical debt

VC firm RA Capital starts a new synthetic biology incubator

Public health communication lessons from Covid

Man killed during FBI raid in connection with threats against Biden, other officials

Wegovy’s successful heart trial raises vital question about weight loss

Friends ask where James Watson's attitudes about race came from

focus

hotspot

focus

Drug repurposing or repositioning? The language matters

Wegovy’s successful heart trial raises vital question about weight loss

In age of alternative facts, a scholarly course on calling out crap

Naloxone nonprofit donates 200,000 doses after FDA approval

Jerome Adams on the need for new antivirals for Covid

Police still searching for prisoner who escaped from NYC hospital

Guidelines to prevent youth baseball injuries need more muscle

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

The cancer drug shortage isn’t new — and neither are the solutions

VC firm RA Capital starts a new synthetic biology incubator

focus

In same hospitals, Black patients receive fewer opioids than white patients

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

South Korea throws huge K

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

VC firm RA Capital starts a new synthetic biology incubator

Biden to sign 'historic' executive order on how US military handles sexual assault cases

focus

focus

explore

focus